Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | Gpr183 | Rat | 1,2-dimethylhydrazine | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | 1,2-Dimethylhydrazine results in increased expression of GPR183 mRNA | CTD | PMID:22206623 | Gpr183 | Rat | 17beta-estradiol | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [Estradiol co-treated with Norethindrone Acetate] results in decreased expression of GPR183 mRNA | CTD | PMID:22217510 | Gpr183 | Rat | 17beta-estradiol | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Estradiol results in increased expression of GPR183 mRNA | CTD | PMID:31614463 | Gpr183 | Rat | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | 2,2',4,4'-tetrabromodiphenyl ether analog results in decreased expression of GPR183 mRNA | CTD | PMID:19095052 | Gpr183 | Rat | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression more ... | CTD | PMID:25975270 | Gpr183 | Rat | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of GPR183 mRNA | CTD | PMID:34747641 | Gpr183 | Rat | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of GPR183 mRNA | CTD | PMID:26290441 | Gpr183 | Rat | 2,4-dibromophenyl 2,4,5-tribromophenyl ether | affects expression | ISO | Gpr183 (Mus musculus) | 6480464 | 2,2',4,4',5-brominated diphenyl ether affects the expression of GPR183 mRNA | CTD | PMID:38648751 | Gpr183 | Rat | 2-hydroxypropanoic acid | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Lactic Acid results in increased expression of GPR183 mRNA | CTD | PMID:30851411 | Gpr183 | Rat | 4-hydroxynon-2-enal | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | 4-hydroxy-2-nonenal results in increased expression of GPR183 mRNA | CTD | PMID:19191707 | Gpr183 | Rat | 4-hydroxyphenyl retinamide | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of GPR183 mRNA | CTD | PMID:28973697 | Gpr183 | Rat | acetamide | increases expression | EXP | | 6480464 | acetamide results in increased expression of GPR183 mRNA | CTD | PMID:31881176 | Gpr183 | Rat | albendazole | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA | CTD | PMID:16861626 | Gpr183 | Rat | alpha-Zearalanol | increases expression | EXP | | 6480464 | Zeranol results in increased expression of GPR183 mRNA | CTD | PMID:35163327 | Gpr183 | Rat | antirheumatic drug | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Antirheumatic Agents results in decreased expression of GPR183 mRNA | CTD | PMID:24449571 | Gpr183 | Rat | arotinoid acid | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF more ... | CTD | PMID:34480604 | Gpr183 | Rat | arsenous acid | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Arsenic Trioxide results in increased expression of GPR183 mRNA | CTD | PMID:15761015 | Gpr183 | Rat | benzo[a]pyrene | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of GPR183 mRNA | CTD | PMID:20064835 | Gpr183 | Rat | benzo[a]pyrene | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | AHR protein affects the reaction [Benzo(a)pyrene affects the expression of GPR183 mRNA]; Benzo(a)pyrene promotes the more ... | CTD | PMID:19654925|PMID:22228805 | Gpr183 | Rat | benzo[a]pyrene | decreases methylation | ISO | GPR183 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of GPR183 5' UTR; Benzo(a)pyrene results in decreased methylation of more ... | CTD | PMID:27901495 | Gpr183 | Rat | benzo[a]pyrene | increases methylation | ISO | Gpr183 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased methylation of GPR183 3' UTR; Benzo(a)pyrene results in increased methylation of more ... | CTD | PMID:27901495 | Gpr183 | Rat | benzo[a]pyrene | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of GPR183 mRNA | CTD | PMID:21569818 | Gpr183 | Rat | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of GPR183 mRNA | CTD | PMID:25181051|PMID:34947998 | Gpr183 | Rat | bisphenol A | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of GPR183 gene | CTD | PMID:31601247 | Gpr183 | Rat | bisphenol A | affects methylation | ISO | GPR183 (Homo sapiens) | 6480464 | bisphenol A affects the methylation of GPR183 gene | CTD | PMID:31601247 | Gpr183 | Rat | buta-1,3-diene | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | 1,3-butadiene results in decreased expression of GPR183 mRNA | CTD | PMID:29038090 | Gpr183 | Rat | Butylbenzyl phthalate | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | butylbenzyl phthalate results in increased expression of GPR183 mRNA | CTD | PMID:28392331 | Gpr183 | Rat | Butylbenzyl phthalate | decreases methylation | ISO | Gpr183 (Mus musculus) | 6480464 | butylbenzyl phthalate results in decreased methylation of GPR183 intron | CTD | PMID:28392331 | Gpr183 | Rat | butyric acid | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Butyric Acid results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | cadmium atom | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPR183 more ... | CTD | PMID:35301059 | Gpr183 | Rat | cadmium dichloride | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPR183 more ... | CTD | PMID:35301059 | Gpr183 | Rat | cannabidiol | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Cannabidiol results in decreased expression of GPR183 mRNA | CTD | PMID:21542829 | Gpr183 | Rat | carbon nanotube | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Nanotubes, Carbon results in increased expression of GPR183 mRNA | CTD | PMID:25554681 | Gpr183 | Rat | carbon nanotube | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Nanotubes, Carbon results in decreased expression of GPR183 mRNA | CTD | PMID:25926378 | Gpr183 | Rat | CHIR 99021 | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF more ... | CTD | PMID:34480604 | Gpr183 | Rat | chloroprene | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Chloroprene results in decreased expression of GPR183 mRNA | CTD | PMID:23125180 | Gpr183 | Rat | cisplatin | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Cisplatin results in increased expression of GPR183 mRNA | CTD | PMID:27594783 | Gpr183 | Rat | cortisol | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF more ... | CTD | PMID:34480604 | Gpr183 | Rat | crocidolite asbestos | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Asbestos, Crocidolite results in decreased expression of GPR183 mRNA | CTD | PMID:29279043 | Gpr183 | Rat | Cuprizon | increases expression | EXP | | 6480464 | Cuprizone results in increased expression of GPR183 mRNA | CTD | PMID:27523638 | Gpr183 | Rat | diarsenic trioxide | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Arsenic Trioxide results in increased expression of GPR183 mRNA | CTD | PMID:15761015 | Gpr183 | Rat | dimethylarsinic acid | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results more ... | CTD | PMID:34876320 | Gpr183 | Rat | diquat | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Diquat results in decreased expression of GPR183 mRNA | CTD | PMID:36851058 | Gpr183 | Rat | doxorubicin | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of GPR183 mRNA | CTD | PMID:29803840 | Gpr183 | Rat | doxorubicin | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Doxorubicin results in decreased expression of GPR183 mRNA | CTD | PMID:39631538 | Gpr183 | Rat | entinostat | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | entinostat results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | ethyl methanesulfonate | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in decreased expression of GPR183 mRNA | CTD | PMID:23649840 | Gpr183 | Rat | ferric oxide | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | ferric oxide analog results in increased expression of GPR183 mRNA | CTD | PMID:24525745 | Gpr183 | Rat | fulvestrant | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of GPR183 gene | CTD | PMID:31601247 | Gpr183 | Rat | furan | increases expression | EXP | | 6480464 | furan results in increased expression of GPR183 mRNA | CTD | PMID:27387713 | Gpr183 | Rat | GSK-J4 | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | GSK-J4 results in increased expression of GPR183 mRNA | CTD | PMID:29301935 | Gpr183 | Rat | HC toxin | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | HC toxin results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | irinotecan | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Irinotecan metabolite results in increased expression of GPR183 mRNA; Irinotecan results in increased expression of more ... | CTD | PMID:15956246 | Gpr183 | Rat | ivermectin | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA | CTD | PMID:16861626 | Gpr183 | Rat | L-ascorbic acid | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with more ... | CTD | PMID:34480604 | Gpr183 | Rat | L-ascorbic acid 2-phosphate | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA more ... | CTD | PMID:34480604 | Gpr183 | Rat | lead diacetate | increases expression | EXP | | 6480464 | lead acetate results in increased expression of GPR183 mRNA | CTD | PMID:22641619 | Gpr183 | Rat | lipopolysaccharide | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | Lipopolysaccharides results in decreased expression of GPR183 mRNA | CTD | PMID:25890327 | Gpr183 | Rat | lipopolysaccharide | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of GPR183 mRNA; [S-(1,2-dichlorovinyl)cysteine more ... | CTD | PMID:18192897|PMID:35811015 | Gpr183 | Rat | methotrexate | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Methotrexate results in decreased expression of GPR183 mRNA | CTD | PMID:17400583 | Gpr183 | Rat | methyl methanesulfonate | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of GPR183 mRNA | CTD | PMID:23649840 | Gpr183 | Rat | methylarsonic acid | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results more ... | CTD | PMID:34876320 | Gpr183 | Rat | methylisothiazolinone | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | 2-methyl-4-isothiazolin-3-one results in increased expression of GPR183 mRNA | CTD | PMID:31629900 | Gpr183 | Rat | mocetinostat | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | mocetinostat results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | Muraglitazar | decreases expression | EXP | | 6480464 | muraglitazar results in decreased expression of GPR183 mRNA | CTD | PMID:21515302 | Gpr183 | Rat | nickel atom | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Nickel results in increased expression of GPR183 mRNA | CTD | PMID:25583101 | Gpr183 | Rat | ozone | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased more ... | CTD | PMID:34911549 | Gpr183 | Rat | ozone | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [Air Pollutants results in increased abundance of Ozone] which affects the expression of GPR183 mRNA | CTD | PMID:35430440 | Gpr183 | Rat | panobinostat | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Panobinostat results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | paracetamol | affects expression | ISO | Gpr183 (Mus musculus) | 6480464 | Acetaminophen affects the expression of GPR183 mRNA | CTD | PMID:17562736 | Gpr183 | Rat | pioglitazone | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Pioglitazone results in decreased expression of GPR183 mRNA | CTD | PMID:30031879 | Gpr183 | Rat | rac-lactic acid | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Lactic Acid results in increased expression of GPR183 mRNA | CTD | PMID:30851411 | Gpr183 | Rat | rosuvastatin calcium | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA] | CTD | PMID:18192897 | Gpr183 | Rat | rosuvastatin calcium | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Rosuvastatin Calcium results in increased expression of GPR183 mRNA | CTD | PMID:18192897 | Gpr183 | Rat | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of GPR183 mRNA; [S-(1,2-dichlorovinyl)cysteine more ... | CTD | PMID:35811015 | Gpr183 | Rat | SB 431542 | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [LDN 193189 co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with EGF protein co-treated with FGF2 protein] results in more ... | CTD | PMID:34480604 | Gpr183 | Rat | sodium arsenate | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results more ... | CTD | PMID:34876320 | Gpr183 | Rat | sodium arsenate | decreases expression | ISO | Gpr183 (Mus musculus) | 6480464 | sodium arsenate results in decreased expression of GPR183 mRNA | CTD | PMID:39847705 | Gpr183 | Rat | sodium arsenite | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of GPR183 mRNA | CTD | PMID:38568856 | Gpr183 | Rat | sodium arsenite | multiple interactions | ISO | Gpr183 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results more ... | CTD | PMID:34876320 | Gpr183 | Rat | sunitinib | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of GPR183 mRNA | CTD | PMID:31533062 | Gpr183 | Rat | tacedinaline | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | tacedinaline results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | Tesaglitazar | decreases expression | EXP | | 6480464 | tesaglitazar results in decreased expression of GPR183 mRNA | CTD | PMID:21515302 | Gpr183 | Rat | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of GPR183 mRNA | CTD | PMID:34492290 | Gpr183 | Rat | titanium dioxide | increases expression | EXP | | 6480464 | titanium dioxide results in increased expression of GPR183 mRNA | CTD | PMID:30012374 | Gpr183 | Rat | trichloroethene | decreases expression | EXP | | 6480464 | Trichloroethylene results in decreased expression of GPR183 mRNA | CTD | PMID:33387578 | Gpr183 | Rat | trichostatin A | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | triclosan | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Triclosan results in decreased expression of GPR183 mRNA | CTD | PMID:30510588 | Gpr183 | Rat | trimellitic anhydride | increases expression | ISO | Gpr183 (Mus musculus) | 6480464 | trimellitic anhydride results in increased expression of GPR183 mRNA | CTD | PMID:19042947 | Gpr183 | Rat | troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of GPR183 mRNA | CTD | PMID:21515302 | Gpr183 | Rat | tunicamycin | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Tunicamycin results in increased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | valproic acid | affects expression | ISO | Gpr183 (Mus musculus) | 6480464 | Valproic Acid affects the expression of GPR183 mRNA | CTD | PMID:17963808 | Gpr183 | Rat | valproic acid | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | vorinostat | decreases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Vorinostat results in decreased expression of GPR183 mRNA | CTD | PMID:33770205 | Gpr183 | Rat | XAV939 | multiple interactions | ISO | GPR183 (Homo sapiens) | 6480464 | [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA more ... | CTD | PMID:34480604 | Gpr183 | Rat | zinc atom | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Zinc deficiency results in increased expression of GPR183 mRNA | CTD | PMID:18356318 | Gpr183 | Rat | zinc(0) | increases expression | ISO | GPR183 (Homo sapiens) | 6480464 | Zinc deficiency results in increased expression of GPR183 mRNA | CTD | PMID:18356318 | | |||||||||||||||||||





















